Injectable Biologic Articles & Analysis
5 articles found
The current paradigm of injectable drug delivery has stagnated since the early 2000s. Despite recent innovations, like the launch in Europe of the first electromechanical reusable and connected auto-injector (UCB’s CIMZIA ava Connect® in early 2021), almost all new biologic drugs are launched with specific and undifferentiated ...
(NASDAQ:RANI) is developing a disruptive technology to solve the problem of converting biologic injectable drugs, including antibodies, peptides and proteins, into oral therapies with its RaniPill that bypasses destruction in the stomach to deliver its payload to the vascular intestinal wall in the GI tract. ...
Rani Therapeutics, a clinical-stage biotherapeutics company, based in San Jose, CA, is developing orally-administered biologics. Their novel, patented platform technology replaces subcutaneous or IV injection of biologics with oral dosing. ...
Rani Therapeutics offers a breakthrough capsule, the RaniPill which could change the way patients with chronic conditions take medication by eliminating the need for painful injections. Rani Therapeutics is a clinical-stage biotherapeutics company offering an alternative to painful injections for patients with chronic conditions such as neuroendocrine ...
Rani, A Platform Technology Company: Rani's proprietary platform technology, the RaniPill capsule, intends to replace subcutaneous or intravenous injections of biologics with oral dosing. RaniPill helps convert injectable biologic drugs such as TNF-alpha inhibitors, interleukin antibodies and basal insulin, among others, into ...